Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves

Clinical Research in Cardiology

Volumn 105, Issue 3, 2016, Pages 268-272

  Yadlapati, Ajay ^a   Groh, Christopher ^a   Malaisrie, S Chris ^a   Gajjar, Mark ^a   Kruse, Jane ^a   Meyers, Sheridan ^a   Passman, Rod ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Atrial flutter; Bioprosthetic; Novel anticoagulants; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CREATININE; DABIGATRAN; RIVAROXABAN;

ARTICLE; ATRIAL FIBRILLATION; AUTOPSY; BIOPROSTHETIC VALVE; BLEEDING; BLOOD VESSEL OCCLUSION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHADS2 SCORE; COMORBIDITY; CREATININE CLEARANCE; DEVICE SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FLUTTER; HEART VALVE REPLACEMENT; HEMARTHROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MECHANICAL HEART VALVE; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VISUAL ANALOG SCALE; ADVERSE EFFECTS; AGED; ATRIAL FLUTTER; BIOPROSTHESIS; CHEMICALLY INDUCED; COMPLICATION; DEVICES; HEART VALVE PROSTHESIS; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROSTHESIS DESIGN; STROKE; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BIOPROSTHESIS; FEMALE; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84942050158     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-015-0919-z     Document Type: Article

References (24)

1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M (2006) Burden of valvular heart diseases: a population-based study. Lancet 368:1005–1011
2. Sun JC, Davidson MJ, Lamy A, Eikelboom JW (2009) Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 374:565–576
3. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X (2013) Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 112:1142–1147
4. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F, Investigators R-A (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369:1206–1214
5. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8:202–204
6. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013) Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104
7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
8. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992
9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, Investigators RA (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891
10. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD (2014) 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:2438–2488
11. Russo A, Grigioni F, Avierinos JF, Freeman WK, Suri R, Michelena H, Brown R, Sundt TM, Enriquez-Sarano M (2008) Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol 51:1203–1211
12. Grunkemeier GL, Li HH, Naftel DC, Starr A, Rahimtoola SH (2000) Long-term performance of heart valve prostheses. Curr Probl Cardiol 25:73–154
13. Spencer FC, Baumann FG, Grossi EA, Culliford AT, Galloway AC (1986) Experiences with 1643 porcine prosthetic valves in 1492 patients. Ann Surg 203:691–700
14. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ et al (1995) High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 25:1111–1119
15. Berkowitz SD (2001) Antithrombotic therapy after prosthetic cardiac valve implantation: potential novel antithrombotic therapies. Am Heart J 142:7–13
16. Dewanjee MK, Gross DR, Zhai P, Lanzo S, Shim H, Park K, Schaeffer DJ, Twardock AR (1999) Thrombogenicity of polyethylene oxide-bonded Dacron sewing ring in a mechanical heart valve. J Heart Valve Dis 8:324–330
17. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962
18. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, RE-LY Investigators (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376:975–983
19. Tamayo S, Frank Peacock W, Patel M, Sicignano N, Hopf KP, Fields LE, Sarich T, Wu S, Yannicelli D, Yuan Z (2015) Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 38:63–68
20. Steiner T, Bohm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Rother J, Schellinger PD, Spannagl M, Veltkamp R (2013) Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 102:399–412
21. Jamieson WR, Ling H, Burr LH, Fradet GJ, Miyagishima RT, Janusz MT, Lichtenstein SV (1998) Carpentier–Edwards supraannular porcine bioprosthesis evaluation over 15 years. Ann Thorac Surg 66:S49–S52
22. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG (2001) Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 119:220S–227S
23. Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, D’Amico R, Beghi C (2004) Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation 110:496–500
24. Aramendi JI, Mestres CA, Martinez-Leon J, Campos V, Munoz G, Navas C (2005) Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 27:854–860